FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis

Dr. Rivera was part of a team that discovered a possible novel role for FGF-23 in erythrocyte production and differentiation and also suggested elevated FGF-23 levels contribute to the pathogenesis of anemia in patients with CKD and CVD. Published in the Journal of Biological Chemistry on April 2014.